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Introduction: While the impacts of illicit drug use on mortality have been well described, the impact of poly-
substance that includes alcohol has received less attention.We examined the impact of binge alcohol use onmor-
tality among a cohort of people who inject drugs (PWID) in a Canadian setting.
Methods: Using data derived from a prospective cohort study of PWID in Vancouver, Canada recruited between
May 1996 and November 2013. We ascertained dates and causes of death through a conﬁdential linkage with
the provincial registry and examined the impact of binge alcohol use. The primary outcome of interest was all-
cause mortality. We used Cox proportional hazard regression to determine factors associated with mortality, in-
cluding socio-demographic characteristics, drug use patterns and other risk behaviours.
Results:During the study period, 2550 individualswere followed (844 ofwhomwere HIV positive at baseline) for
a median of 75.4 months (interquartile range 37.9–113.2). Of these, 795 (31%) participants reported binge alco-
hol use at some time during the study period. In multivariable analyses, binge alcohol use remained indepen-
dently associated with all-cause-mortality (adjusted hazard ratio = 1.41; 95% conﬁdence interval: 1.06–1.88)
after adjustment for other drug use patterns.
Conclusions: Binge alcohol use was associated with time to all-cause mortality among PWID in this setting. Since
alcohol use is often overlooked as a risk factor for mortality among this population, these ﬁndings highlight the
continued need to incorporate addiction treatment and public health interventions and policies that address
binge alcohol use to reduce alcohol related-harms.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Approximately 11–21 million people inject drugs worldwide
(Degenhardt & Hall, 2012). Injection drug use is a well established-
risk factor for increased morbidity and mortality (Degenhardt, Bucello,
et al., 2011; Mathers & Degenhardt, 2014; Mathers et al., 2013; Miller,
Kerr, Strathdee, Li, &Wood, 2007) with previous studies demonstrating
that themortality for people who inject drugs (PWID) exceeds the gen-
eral population by as much as 13 to 15 times (Hulse, English, Milne, &
Holman, 1999; Mathers et al., 2013). Previous studies have denoted
that fatal overdose accounts for the majority of deaths in the illicit
drug using population (Degenhardt, Bucello, et al., 2011; Mathersr Excellence in HIV/AIDS, 608-
Johnson), hdong@cfenet.ubc.ca
cfenet.ubc.ca (K. Hayashi),
ca (T. Kerr),
. This is an open access article underet al., 2013). Though other acute and chronic diseases also contribute
to mortality for PWID the majority of non-overdose related deaths are
attributable to preventable risk factors including infectious disease
such as HIV as well as suicide (Miller et al., 2007).
Although alcohol consumption patterns vary geographically (Rehm
et al., 2003), alcohol use disorder (AUD) is one of the most prevalent
substance use disorders with an estimated 3.6% of adults affected glob-
ally (J Rehmet al., 2009). In Canada in 2012, 18.1% of the populationmet
the criteria for AUD in their lifetime and 3.2% of the population met the
same criteria over the last 12 months (Pearson, Janz, & Ali, 2013). AUDs
inﬂict one of the largest burdens onmortality globally and are estimated
to account for the largest years of life lostwithinmental health and sub-
stance use disorders at 44.4%, with the largest burden occurring among
working age adults (Whiteford et al., 2013). AUD also has a large impact
on the non-fatal burden of disease and is estimated to account for 9.6%
of disability-adjusted-life years lost worldwide and an estimated 7.9%
of years of life lived with disability (Whiteford et al., 2013). Individuals
with AUD have a highmortality risk, with individuals in clinical settings
estimated to be three to ﬁve times greater risk for death,withwomen at
an increased risk in comparison to men (Roerecke & Rehm, 2013).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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contributor to overdose mortality. The impact of the use of central ner-
vous systemdepressants such as alcohol on fatal and non-fatal overdose
has been well described with opioid injection drug use (Degenhardt,
Bucello, et al., 2011; Kerr et al., 2007; White, Hingson, Pan, & yi, 2011),
with one study reporting an increased mortality risk by as much as
69% (Fischer et al., 2004). In New York City between 1990 and 1998,
the combination of alcohol, opioids and cocaine was shown to be the
most common cause of overdose death, accounting for 97.6% of all over-
dose deaths (Cofﬁn et al., 2003). Another study in California showed a
two-fold increase in nonfatal overdose for PWIDwho reported drinking
alcohol 17 out of the last 30 days (Martinez, D'Amico, Kral, &
Bluthenthal, 2012). In this study, 19% of participants reported drinking
alcohol daily in the last 30 days (Martinez et al., 2012). Although this ev-
idence suggests the importance of understanding the impact of alcohol
on overdose mortality, there are limited data that explore the impact of
binge alcohol use patterns on all-cause mortality among PWID. There-
fore, thepresent studywas undertaken to examine the effect of binge al-
cohol use on mortality in PWID in a Canadian setting.2. Materials and methods
Our study was performed using data from the Vancouver Injection
Drug Users Study (VIDUS) and AIDS Care Cohort to Evaluate Access to
Survival Services (ACCESS), which are longstanding prospective cohorts
of PWID operating in the Downtown Eastside of Vancouver, Canada.
Both studies share identical recruitment and follow-up procedures,
allowing for pooling of the data, with the only variance between the co-
horts being that the ACCESS cohort includes only HIV-positive individ-
uals and includes injection and non-injection drug users whereas
VIDUS includes only HIV-negative PWID. Detailed descriptions of sam-
pling and recruitment procedures for both cohorts have been described
elsewhere (Milloy et al., 2012; Strathdee, Palepu, Cornelisse, et al., 1998;
Tyndall et al., 2003).
Eligibility criteria included participants aged 18 years or older, any
illicit drug use other than cannabinoids in the previous month (for
ACCESS) or any injection drug use in the previous month (for VIDUS)
and a current resident of the Greater Vancouver Regional District.
All participants provided written and informed consent and are
compensated ($20) their time and transportation for each study visit.
These cohorts receive annual approval from the University of British
Columbia/Providence Healthcare Research Ethics Board.
At baseline and semi-annually thereafter, participants complete an
interviewer-administered questionnaire and provide blood samples.
Questionnaires ascertain a range of data including demographic charac-
teristics, injection and non-injection drug use and sexual risk behav-
iours. All interviews occur in a private space with pre- and post-test
counsellingprovided by trained study nurses. Participantswho test pos-
itive for antibodies to HIV or Hepatitis C virus (HCV) are referred for on-
going health care. Individuals known to be HIV-positive provide blood
samples for ongoing HIV disease monitoring.
Using a conﬁdential linkagewith the British Columbia Vital Statistics
Agency, we ascertained dates and causes of death among study partici-
pants and through ongoing locator contacts provided by study partici-
pants. The Vital Statistics database recorded causes of death according
to International Classiﬁcation of Diseases (ICD), 10th edition. Both
studies are observational and do not include any active study interven-
tions. Participants in the VIDUS cohort that seroconvert during the study
period are offered continued study participation in the ACCESS
(HIV-positive) cohort.
The present study was restricted to individuals with a history of
injecting drugs who were recruited between May 1996 and November
2013. To avoid potential bias relating to long durations between the
last date of study visit where behavioural information was assessed
and the date of death (i.e., loss to regular follow up), individuals whowere identiﬁed as deceased more than 24 months after the last fol-
low-up visit were censored on the date of the last follow up.
Our primary outcome of interest was time to death (all-cause). The
primary explanatory variable of interest was binge alcohol use, deﬁned
by answering “Yes” to the question, “Have you binged on alcohol in the
last 6 months (that is when you used alcohol more than usual)?”. We
also considered a number of substance use behaviours in the previous
six months including ≥daily heroin injection (yes vs. no), ≥daily
cocaine injection (yes vs. no), ≥daily crack cocaine smoking (yes vs.
no) and ≥daily amphetamine injection (yes vs. no). Other variables in-
cluded: age (per 10 years older); gender (male vs. female); ethnicity
(Caucasian vs. non-Caucasian); living in unstable housing (yes vs. no);
HIV serostatus (positive vs. negative) and enrolment in methadone
maintenance treatment (yes vs. no). These time-updated variables re-
ferred to exposures occurring in the six-month period prior to each
study interview. As previously deﬁned, unstable housing includes living
in single room occupancy hotels, shelters or other transitional housing
or living on the street (Spittal et al., 2002; Wood et al., 2007).
First, we examined baseline characteristics of the study sample,
stratiﬁed by self-reported binge alcohol use in the previous 6 months.
The initial analysis included the Chi-square test for dichotomous
variables and the Wilcoxon rank sum test for continuous variables.
All-causemortality rate and 95% conﬁdence intervals [CI] were calculat-
ed using the Poisson distribution.
Next, we used bivariable Cox proportional hazard regression to ex-
amine the relationship between each explanatory variable and time to
death. All behavioural variables were treated as time-varying variables.
To ﬁt the multivariable model, we employed a conservative stepwise
backward selection approach, as previously described in full (Lima
et al., 2012; Milloy et al., 2011). In brief, we included all variables
found to be signiﬁcantly associated with time to death in bivariable
analyses at p b 0.10 in a multivariable model, and used a stepwise ap-
proach to ﬁt a series of reduced models. After comparing the value of
the coefﬁcient associated with binge alcohol use in the full model to
the value of the coefﬁcient in each of the reduced models, we dropped
the secondary variable associated with the smallest relative change.
We continue this iterative process until the minimum change exceeded
5%. Remaining variables were considered as potential confounders in a
ﬁnal multivariable model.
3. Results
A total of 2854 individuals were recruited during the study period
between and May 1996 and November 2013. Among these 304
(10.7%) participants were excluded as a result of only having a baseline
study visit, lacking of either follow-up visit or death date within
24 months from baseline. In comparison to those included in the pres-
ent study, those excludedwere younger (p= b0.001) but had no signif-
icant differences in gender, ethnicity and binge alcohol use (p N 0.05).
Overall, the study sample was followed for a median of 75.4 months
(inter-quartile range [IQR]: 37.9–113.2). At baseline, 1687 were male
(66.2%), 1541 reported Caucasian ethnicity (60.4%), the median age
was 37.7 years (IQR: 29.9–44.2) and 381 (15%) reported binge alcohol
use in the previous six months. At baseline, 971 (36%) individuals re-
ported ≥daily heroin injection in the previous six months, 735 (28.8%)
reported ≥ injected cocaine daily, 614 (24.1%) reported ≥daily crack co-
caine smoking and 44 (1.7%) injected amphetamines ≥daily. As shown
in Table 1, at baseline, those who reported binge alcohol use were
more likely to be younger (median age: 34.6 years vs. 38.3 years,
p b 0.001), less likely to be enrolled in methadone maintenance treat-
ment (odds ratio [OR] = 0.19; 95% CI: 0.12–0.29) and less likely to be
HIV positive (OR = 0.63; 95% CI: 0.49–0.81). In terms of drug use pat-
terns, binge alcohol usewas negatively associatedwith ≥daily heroin in-
jection (OR = 0.60; 95% CI: 0.47–0.76) and ≥daily crack cocaine
smoking (OR = 0.50; 95% CI: 0.37–0.67) and positively associated
with ≥daily cocaine injection (OR = 1.61; 95% CI: 1.28–2.02).
Table 1
Baseline characteristics of 2550 people who use injection drugs, stratiﬁed by binge alcohol use in the last 6 months, in Vancouver, Canada, 1996–2013.
Characteristic Total
N = 2550 (%)
Binge alcohol
n = 381
No binge alcohol
n = 2164
Odds ratio (95% CI) p-Value
Gender
Male 1687 (66.2) 252 (66.1) 1432 (66.2) 1.00 (0.79, 1.26) 0.990
Female 863 (33.8) 129 (33.9) 732 (33.8)
Age†
Median (IQR) 37.7 (29.9–44.2) 34.6 (27.0–41.3) 38.3 (30.6–44.8) b0.001
Caucasian ethnicity
Yes 1541 (60.4) 174 (45.7) 1363 (63.0) 0.49 (0.40, 0.62) b0.001
No 1009 (39.6) 207 (54.3) 801 (37.0)
Unstable housing⁎
Yes 1770 (69.4) 254 (66.7) 1512 (69.9) 0.87 (0.69, 1.10) 0.233
No 759 (29.8) 123 (32.3) 635 (29.3)
HIV serostatus⁎
Positive 844 (33.1) 95 (24.9) 746 (34.5) 0.63 (0.49, 0.81) b0.001
Negative 1705 (66.9) 285 (74.8) 1418 (65.5)
Enrolment in MMT⁎
Yes 594 (23.3) 24 (6.3) 569 (26.3) 0.19 (0.12, 0.29) b0.001
No 1946 (76.3) 357 (93.7) 1586 (73.3)
≥Daily heroin injection⁎
Yes 917 (36.0) 101 (26.5) 814 (37.6) 0.60 (0.47, 0.76) b0.001
No 1627 (63.8) 279 (73.2) 1345 (62.2)
≥Daily cocaine injection⁎
Yes 735 (28.8) 143 (37.5) 590 (27.3) 1.61 (1.28, 2.02) b0.001
No 1799 (70.5) 235 (61.7) 1561 (72.1)
≥Daily crack cocaine smoking⁎
Yes 614 (24.1) 56 (14.7) 557 (25.7) 0.50 (0.37, 0.67) b0.001
No 1933 (75.8) 325 (85.3) 1604 (74.1)
≥Daily amphetamine injection⁎
Yes 44 (1.7) 1 (0.3) 43 (2.0) 0.13 (0.02, 0.94) 0.010†
No 2500 (98.0) 380 (99.7) 2115 (97.7)
Note: CI = conﬁdence interval; IQR = interquartile range; MMT =methadone maintenance treatment.
† p-Value Fisher's exact test report as ‘yes’ sample N = 1.
⁎ Behaviours and status in the last 6 months.
Table 2
Bivariable and multivariable analyses of time to all-cause death among 2550 people who
use injection drugs, Vancouver, Canada, 1996–2013.
Variable Unadjusted hazard ratio Adjusted hazard ratio†
HR (95% CI) p-Value HR (95% CI) p-Value
Binge alcohol use⁎
(Yes vs. no) 1.38 (1.05–1.83) 0.023 1.41 (1.06–1.88) 0.018
Gender
(Male vs. female) 1.08 (0.91–1.30) 0.372
Age
(Per 10-year older) 1.26 (1.15–1.38) b0.001 1.29 (1.17–1.42) b0.001
Ethnicity
(Caucasian vs.
non-Caucasian)
1.07 (0.90–1.28) 0.421
Unstable housing⁎
(Yes vs. no) 1.34 (1.13–1.60) b0.001
HIV serostatus⁎
(Positive vs.
negative)
2.49 (2.10–2.96) b0.001 2.53 (2.12–3.01) b0.001
Enrolment in MMT*
(Yes vs. no) 0.80 (0.68–0.95) 0.013 0.80 (0.67–0.95) 0.010
≥Daily heroin
injection⁎
(Yes vs. no) 0.81 (0.65–1.02) 0.069
≥Daily cocaine
injection⁎
1.44 (1.15–1.80) 0.002
(Yes vs. no) 1.46 (1.17–1.82) b0.001
≥Daily crack cocaine
smoking⁎
(Yes vs. no) 0.89 (0.73–1.08) 0.250
≥Daily amphetamine
injection⁎
(Yes vs. no) 0.24 (0.06–0.96) 0.043
Note: CI = conﬁdence interval; HR = hazard ratio; MMT = methadone maintenance
treatment.
⁎ Behaviours and status in the last six months.
† Model was adjusted for age, HIV serostatus, daily cocaine injection and enrolment in
methadone maintenance treatment.
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hol use at any follow-up visit. Overall, 530 individuals died for an inci-
dence density of 2.9 (95% CI: 2.7–3.2) deaths per 100 person years.
The primary causes of death included HIV related mortality (23.4%), ac-
cidental poisonings (22.1%), unspeciﬁed causes (13.8%) and cardiovas-
cular disease (6.3%).
Table 2 shows the bivariable andmultivariable Cox regression results
examining for a potential association between binge alcohol use and
time to death. In the bivariable analyses, binge alcohol usewas positively
associated with mortality with a (hazard ratio of 1.38 [95% CI: 1.05–
1.83]). After adjusting for potential confounders including age, HIV
serostatus, daily cocaine injection and enrolment in methadone mainte-
nance treatment, in themultivariable model binge alcohol use remained
independently and positively associated with time to all-cause mortality
(adjusted hazard ratio [AHR] = 1.41 [95% CI: 1.06–1.88]).
4. Discussion
In the present analysis, we found that binge alcohol use was inde-
pendently associated with an increased risk for all-cause mortality
after adjusting for potential confounders including demographic and
drug use characteristics. These variables are known risk factors and
were included to adjust for their potential confounding effects
(Mathers et al., 2013). The most common causes of death were
HIV/AIDS-associated mortality and overdose.
Our ﬁndings that binge alcohol use is associated with an increased
risk for mortality is unique as we are unaware of any study that specif-
ically examined binge alcohol use and all-cause mortality risk for PWID.
Nevertheless, ourﬁndings are congruentwith existing literature that fo-
cuses on fatal and non-fatal overdose mortality for PWID, particularly
for opioid users with alcohol use, although such results have varied
across geographic regions in their prediction of morbidity andmortality
(Cofﬁn et al., 2003; Darke, Ross, & Hall, 1996; Fischer et al., 2004; Kaye &
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Sergeev, Karpets, Sarang, & Tikhonov, 2003). One Canadian study,
which focused on overdosemortality, identiﬁed alcohol use as a predic-
tor of overdose in the unadjusted model, however the adjusted model
was not signiﬁcant (Fischer et al., 2004). Another Canadian study that
looked at non-fatal overdose amongpolysubstance users found an inde-
pendent association between daily alcohol use and non-fatal overdose
(OR 1.32 CI: 1.09–1.60) (Kerr et al., 2007). Our other multivariable ﬁnd-
ings are consistent with published literature on increased mortality for
PWID including HIV serostatus (Degenhardt, Bucello, et al., 2011;
Hayden et al., 2014; Lappalainen et al., 2015) and daily cocaine injection
(Degenhardt, Singleton, et al., 2011; Hayden et al., 2014), while partici-
pation in a methadone maintenance therapy was associated with a
negative time to all cause mortality. This suggests the need for a
multi-pronged approach to intervention, including harm reduction
strategies, to address morbidity and mortality among PWID. Such an
approach should also include screening and treatment for binge or
excessive alcohol use.
There are multiple ways that alcohol use is categorized in the litera-
ture; AUDs, alcohol abuse, alcohol dependence, excessive drinking and
binge alcohol use, with a lack of consensus internationally on a
standardized guideline for low risk drinking (Carmen, Angeles, Ana, &
María, 2004). In the United States, binge alcohol use can be deﬁned as
a consuming 5 or more (for males) and 4 or more drinks in 2 h, which
can also be deﬁned as ‘excessive’ drinking (Services, 2004). In Canada,
a set of low risk drinking guidelineswere adopted in 2012, which advise
0–2 standard drinks per day for women (≤10 per week) and 0–3 stan-
dard drinks per day for men (≤15 per week) (Stockwell, Butt,
Beirness, Gliksman, & Paradis, 2012). Excessive or binge drinkers are
at increased risk for developing an AUD (Dawson, 2000) and approxi-
mately 9–10% of binge drinkers will develop an AUD in their lifetime
(Esser et al., 2014). The prevalence of an AUD increases with the fre-
quency of binge drinking episodes (Esser et al., 2014). Interestingly, an
earlier study from our setting, which examined a range of drug use pat-
terns including daily alcohol use, did not ﬁnd an independent associa-
tion between daily alcohol use and increased morality (Hayden et al.,
2014). In contrast, the present study may suggest that binge alcohol
use rather than regular daily use may be an important and distinct
from people who identify as daily drinkers including those who have
not been diagnosed with an AUD but engage in binge or high risk
types of alcohol use. However, additional research with more robust
measures of binge alcohol use is needed to fully elucidate the impact
this predictor of mortality among PWID.
Population-based studies have shown that only 5% of the population
is able to accurately describe low-risk drinking guidelines and short and
long-term harms related to alcohol use (De Visser & Birch, 2012;
Livingston, 2012). This lack of knowledge may lead to an underestima-
tion of alcohol consumption and drinking in excess of the guidelines. In
addition to international standardization of low-risk drinking guidelines,
addiction treatment and public health strategies are needed to enhance
knowledge and prevention. There is a substantial evidence base in
support of programmes and policies to reduce alcohol related-harms;
for example generic psychosocial and developmental programmes
(Foxcroft & Tsertsvadze, 2012) to reduce risk factors for drug and alcohol
use; policies to tax alcohol and restrict its availability; as well as
individually-focused interventions such as screening and brief interven-
tions (Anderson, Chisholm, & Fuhr, 2009; O'Donnell et al., 2014).
There are several limitations to the study. Firstly, this samplewasnot
recruited at random and this may affect the generalizability of the ﬁnd-
ings. Second, much of the data is ascertained through self-reported
measures, particularly for patterns of drug use, and therefore may in-
clude some reporting biases. However, self-reported data has been pre-
viously used to control for potential confounding in observational
studies involving PWID and has been found to be valid (Darke, 1998;
Weatherby et al., 1994). Of note, our primary endpoint was based on
mortality data obtained through the Vital Statistics database. Third,binge alcohol use directly before or at the time of death are not de-
scribed due to the method of self-reporting, which inhibits our ability
to ascertain data as proximal at time of death. Fourth, although migra-
tion rates out of the province for PWID are low, mortality rates may be
underestimated as participants whomay have died outside of the prov-
ince thus not included in the provincial registry. We also censored
events that occurred following a long period (N24 months) between
the ﬁnal study interview and death. Fifth, the dichotomous nature of
the question used to ascertain binge alcohol use as deﬁned in this
study does not provide data for numbers of drinks consumed or
frequency of binge episodes. Finally, as this is a non-randomized
study, there exists the possibility of residual confounding rather than a
causal association between binge alcohol use and mortality. While this
bias was addressed in part by using multivariable adjustment of key
demographic and behavioural predictors of survival, there may be
other unmeasured confounders.
In summary, in this setting, self-reported binge alcohol use was in-
dependently associated with higher rates of all-cause mortality among
PWID. While these ﬁndings are limited by their observational nature,
they reinforce the continued need to incorporate addiction treatment,
public health interventions and policies that address binge alcohol use
to reduce alcohol related-harms.
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